Affomix
Corporation, a pioneer in high performance antibody technology,
announced today a collaboration with City of Hope focused on
establishing the clinical utility of “digital proteomics” with next
generation sequencers. One of the nation’s top cancer research and
treatment centers, City of Hope is a leading provider of molecular
diagnostic testing services and an innovator in clinical genetics
research.
“Collaborations with leading institutes such as City of
Hope will enable us to expand our reach into the clinical diagnostics
and personalized medicine markets. This is a transformative milestone in
the merging of proteomics and genomics.”
In the collaboration, Affomix
will use its high-throughput, automated antibody selection technology to
provide City of Hope with recombinant antibodies that are designed to be
readily tagged with oligonucleotide “zipcodes,” making them compatible
with next generation sequencers. “City of Hope will aim to use these
recombinant antibodies to generate proteomic profiles characteristic of
a number of cancers such as renal and prostate,” said Huiqing Wu, M.D,
associate professor and staff pathologist, City of Hope. “We are looking
forward to exploring next generation sequencing and the Affomix
technology in diagnostics. Digital proteomics is the next frontier in
personalized medicine,” said Jakub Sram, PhD, MBA, Director of Business
Development for City of Hope’s Molecular Diagnostic Laboratory.